Can HIPEC be used against platinum-resistance and for inducing sensitivity to PARP inhibitors in ovarian cancer?

Hyperthermic intraperitoneal chemotherapy (HIPEC) has emerged as a main comprehensive treatment of epithelial ovarian cancer (EOC). Despite much criticism to this approach, HIPEC has shown cost-effective benefits in both progression-free survival and overall survival for high tumor burden with no im...

Full description

Saved in:
Bibliographic Details
Published inCancer drug resistance Vol. 3; no. 3; pp. 666 - 671
Main Authors Batista, Thales Paulo, Dal Molin, Graziela Zibetti
Format Journal Article
LanguageEnglish
Published United States OAE Publishing Inc 01.01.2020
Subjects
surgical procedures
poly (ADP-ribose) polymerases
Injections
hyperthermia
drug therapy
intraperitoneal
induced
peritoneal neoplasms
operative
Online AccessGet full text

Cover

More Information
Summary:Hyperthermic intraperitoneal chemotherapy (HIPEC) has emerged as a main comprehensive treatment of epithelial ovarian cancer (EOC). Despite much criticism to this approach, HIPEC has shown cost-effective benefits in both progression-free survival and overall survival for high tumor burden with no important impairment on patient-reported quality of life. On the other hand, the landscape of EOC treatment is changing rapidly and poly (ADP-ribose) polymerase inhibitors (PARPi) currently play an important role in the management of EOC based on recent trials. At this point, an important question to be scrutinized is what to expect from up-front HIPEC in the era of amazing benefits by the PARPi. Herein, we discuss the promising role of combining PARPi and HIPEC in the management of advanced EOC.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Academic Editor: Frits Peters | Copy Editor: Cai-Hong Wang | Production Editor: Jing Yu
ISSN:2578-532X
DOI:10.20517/cdr.2020.27